Methylene Blue - A therapeutic dye for all seasons?

Journal of Chemotherapy

Volumn 14, Issue 5, 2002, Pages 431-443

  Wainwright, M ^a   Crossley, K B ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anticancer; Antimicrobial; Blood; DNA; Malaria; Methylene Blue; Neuroleptic

Indexed keywords

ACRIDINE DERIVATIVE; ACRIFLAVINE; ALKYLATING AGENT; AMINOACRIDINE; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; AZURE B; CHLOROQUINE; CHLORPROMAZINE; CRYSTAL VIOLET; CYCLOSPORIN A; IFOSFAMIDE; MALACHITE GREEN; MEPACRINE; METHDILAZINE; METHYLENE BLUE; METHYLENE BLUE DERIVATIVE; NEUROLEPTIC AGENT; NEW METHYLENE BLUE; NITRIC OXIDE; PHENOTHIAZINE DERIVATIVE; PHOTOSENSITIZING AGENT; PROFLAVINE; PROMETHAZINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TOLONIUM CHLORIDE; TRIPHENYLMETHANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIMALARIAL ACTIVITY; BLOOD STAIN; CANCER CHEMOTHERAPY; CLINICAL MEDICINE; DEMENTIA; DIAGNOSTIC VALUE; DRUG INDUCED DISEASE; DRUG SYNTHESIS; HISTORY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MUTAGENICITY; NEUROTOXICITY; NONHUMAN; PARAPLEGIA; REVIEW;

EID: 0036810375     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.5.431     Document Type: Review

References (93)

1. Guttmann P, Ehrlich P. Ueber die wirkung des methylenblau bei malaria. Berlin Klin Wochschr 1891; 39: 953-956.
2. Fierz-David HE. Fundamental Processes of Dye Chemistry. New York: Interscience Publishers, 1949.
3. Bernsthen A. Berichte 1883; 16: 2896.
4. DeEds F. Antiseptic value of phenothiazines in urinary tract infections. J Pharmacol 1939; 65: 353-371.
5. Himmelweit F, Marquardt M, Dale H. Collected Papers of Paul Ehrlich. Pergamon, London 1956: 555-558.
6. Schulemann W. Synthetic anti-malarial preparations. Proc Roy Soc Med 1932; 25: 897-905.
7. Wainwright M, Grice NJ, Pye LEC. Phenothiazine photosensitizers part 2. 3,7-Bis(arylamino)phenothiazines. Dyes Pigments 1999; 42: 45-51.
8. Wagner SJ, Skripchenko A, Robinette D, Foley JW, Cincotta L. Factors affecting virus photoinactivation by a series of phenothiazine dyes. Photochem Photobiol 1998; 67: 343-349.
9. Mohr H, Lambrecht B, Selz A. Photodynamic virus inactivation of blood components. Immunol Invest 1995; 24: 73-85.
10. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. Antimalarial dyes revisited: Xanthenes, azines, oxazines, and thiazines. Antimicrob Chemother 1995; 39: 2671-2677.
11. Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother 1997; 40: 319-327.
12. Romanovsky DL. Zur frage der parasitologie und therapie der malaria. St Petersburg Med. Wochenschr1891; 16: 297-315.
13. Leishman WB. A simple and rapid method of producing Romanowsky staining in malarial and other blood films. Br Med J 1901; 2: 757-758.
14. Lewis MR, Goland PP, Sloviter HA. Selective action of certain dyestuffs on sarcomata and carcinomata. Anat Rec 1946; 96: 201-220.
15. Lewis MR, Sloviter HA, Goland PP. In vivo staining and retardation of growth of sarcomata in mice. Anat Rec 1946; 95: 89-96.
16. 131I-methylene blue: Preclinical and clinical experience. Hybridoma 1999; 18: 77-82.
17. Rudensky B. Comparison of a semi-automated new Coulter Methylene Blue method with fluorescence flow cytometry in reticulocyte counting. Scand J Clin Lab Invest 1997; 57: 291-296.
18. Inoue T, Tatsumi N. Evaluation of erythropoiesis by new Methylene Blue staining to establish reticulocyte maturity in bone marrow aspirates and peripheral blood. Acta Cytologica 1991; 35: 479-480.
19. Greenwalt TJ, Steane EA, Lau FO Sweeney-Hammond K. Aging of the human erythrocyte. Prog Clin Biol Res 1980; 43: 195-212.
20. Gliesing M, Halbhuber K-J. Topo-optical studies of gradually disintegrated erythrocyte membrane derivates: Different kinds of ghosts. Acta Histochem 1989; 86: 117-121.
21. Makovitzky J, Bozsoky S, Laszlo E. Topo-optical reactions of the human blood platelet membrane. Histochemistry 1983; 79: 281-287.
22. Taylor KB, Jeffree GM. A new basic metachromatic dye, 1:9-dimethyl Methylene Blue. Histochem J 1969; 1: 199-204.
23. Marshall PN, Bentley SA, Lewis SM. Purified azure B as a reticulocyte stain. J Clin Pathol 1976; 29: 1060-1063.
24. Dewitt LM. Preliminary report of experiments in the vital staining of tubercles. J Infect Dis 1913; 12: 68-92.
25. Lewis JH, DeWitt LM. The continuous injection method in the treatment of experimental tuberculosis. Am Rev Tuberc 1919; 3: 548-552.
26. Browning CH. Chemotherapy with antibacterial dyestuffs, in Experimental Chemotherapy Eds Schnitzer & Hawking, Academic Press, New York 1964: 1-36.
27. Albert A, Rubbo SD, Goldacre RJ, Davey ME, Stone JD. The influence of chemical constitution on antibacterial activity. Part II: A general survey of the acridine series. Br J Exp Pathol 1945; 26: 160-192.
28. Wainwright M. Non-porphyrin photosensitizers in biomedicine. Chem Soc Rev 1996; 25; 351-359.
29. Desai KR, Kapadia SK. Studies on quinoline and phenothiazine. Preparation and antimicrobial activity of 2-morpholino-4-(8′-oxyquinolino)-6-phenylurea-s-triazine and 1,3,7,9-tetrachloro-10-(acetylphenylurea)phenothizine. J Indian Chem Soc 1987; 64: 128-129.
30. Mishra S, Srivastava SK, Srivastava SD. Synthesis of 5-arylidene-2-aryl-3-(phenothiazino/benzotriazoloacetamidyl)-1,3- thiazolidine-4-ones as antiinflammatory, anticonvulsant, analgesic and antimicrobial agents. Indian J Chem B 1997; 36: 826-830.
31. Singh G, Swati S, Sharma AK, Prakash L. Synthesis of benzo[a]phenothiazines as antimicrobial agents. Indian J Heterocycl Chem 1996; 6: 9-14.
32. Schuster FL, Visvesvara GS. Efficacy of novel antimicrobials against clinical isolates of opportunisitic amebas. J Eukaryot Microbiol 1998; 45: 612-618.
33. Chattopadhyay D, Mukherjee T, Pal P, Saha B, Bhadra R. Altered membrane permeability as the basis of bactericidal action of methdilazine. J Antimicrob Chemother 1998; 42: 83-86.
34. Amaral L, Kristiansen JE, Abebe LS, Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996; 38: 1049-53.
35. T'ung T. In vitro photodynamic action of Methylene Blue on Trypanosoma brucei. Proc Soc Exp Biol Med 1938; 38: 29-31.
36. Schultz EW, Krueger AP. Inactivation of Staphylococcus bacteriophage by methylene blue. Proc Soc Exper Biol Med 1928; 26: 100-101.
37. Tuite EM, Kelly JM. Photochemical interactions of methylene blue and analogues with DNA and other biological substrates. J Photochem Photobiol B Biol 1993; 21: 103-124.
38. Girotti AW. Photodynamic lipid peroxidation in biological systems. Photochem Photobiol 1990; 51: 497-509.
39. Korytowski W, Bachowski GJ, Girotti AW. Photoperoxidation of cholesterol in homogeneous solution, isolated membranes, and cells: Comparison of the 5α- and 6β-hydroperoxides as indicators of singlet oxygen intermediacy. Photochem Photobiol 1992; 56: 1-8.
40. Bonnett R. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem Soc Rev 1995; 24: 19-33.
41. Foote CS. Chemical mechanisms of photodynamic action. SPIE 1990; 1S6: 115-126.
42. Zhang, T.; Oyama, T.; Aoshima, A.; Hidaka, H.; Zhao, J.; Serpone, N. Photooxidative N-demethylation of methylene blue in aqueous TiO2 dispersions under UV irradiation. J Photochem Photobiol A Chem 2001; 140: 163-172.
43. Houas A, Lachheb H, Ksibi M, Elaloui E, Guillard C, Herrmann J-M. Photocatalytic degradation pathway of methylene blue in water. Appl Catal B Environmental 2001; 31: 145-157.
44. Jacobi A. Methylthionin hydrochlorid in inoperable cancer. J Am Med Assoc 1906; 47: 1545-1546.
45. Crossley ML, Dreisbach PF, Hofmann CM, Parker RP. Chemotherapeutic dyes. I. 5-Arylalkylamino-9-alkylaminobenzo[a]phenoxazines. J Am Chem Soc 1952; 74: 573-578.
46. Cincotta L, Foley JW, MacEachern T, Lampros E, Cincotta AH. Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas. Cancer Res 1994; 54: 1249-1258.
47. Cincotta L, Szeto D, Lampros E, Hasan T, Cincotta AH. Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Photochem Photobiol 1996; 63: 229-237.
48. Yu DS, Chang SY, Ma CP. Ultrastructural changes of bladder cancer cells following methylene blue-sensitized photodynamic treatment. Eur Urol 1991; 19: 322-6.
49. Williams JL, Stamp J, Devonshire R, Fowler GJS. (1989). Methylene blue and the photodynamic therapy of superficial bladder cancer. J Photochem Photobiol B Biol 1989; 4: 229-233.
50. Orth K, Ruck A, Stanescu A, Beger HG. Intraluminal treatment of inoperable oesophageal tumours by intralesional photodynamic therapy with methylene blue. Lancet 1995; 345: 519-520.
51. Ruck A, Beck G, Heckelsmiller K, Knodlsdorfer U, Genzel F, Orth K. Mechanism of cell destruction and cell protection during Methylene Blue induced PDT. SPIE 1999; 3563: 2-10.
52. Potts AM. Further studies concerning the accumulation of polycyclic compounds on uveal melanin. Invest Ophthalmol 1964; 3: 399-405.
53. Link EM, Lukiewicz S. A new radioactive drug selectively accumulating in melanoma cells. Eur J Nucl Med 1982; 7: 469-473.
54. 211At-methylene blue for pigmented melanoma in an animal model system. Cancer Res 1989; 49: 4332-4337.
55. Rice L, Wainwright M, Phoenix DA. Phenothiazine photosensitizers III. Activity of Methylene Blue derivatives against pigmented melanoma cell lines. J Chemother 2000; 12: 94-104.
56. Canto MIF, Setrakian S, Petras RE, Blades E, Chak A, Sivak MV. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 1996; 44: 1-7.
57. Wo JM, Ray MB, Mayfield-Stokes S, et al. Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: A preliminary study. Gastrointest Endosc 2001; 54: 294-301.
58. Onofre MA, Sposto MR, Navarro CM. Reliability of toluidine blue application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont 2001; 91: 535-40.
59. Orloff LA. Methylene blue and sestamibi: Complementary tools for localizing parathyroids. Laryngoscope 2001; 111: 1901-1904.
60. Wainwright M, Phoenix DA, Marland J, Wareing DRA, Bolton FJ. A study of the photobactericidal properties of the phenothiazinium series. FEMS Immunol Med Microbiol 1997; 19: 75-80.
61. Wainwright M, Phoenix DA, Laycock SL, Wareing DRA, Wright PA. Photobactericidal activity of phenothiazinium dyes against methicillin-resistant strains of Staphylococcus aureus. FEMS Microbiol Lett 1998; 160: 177-181.
62. Kim SY, Kwon OJ, Park JW. Inactivation of catalase and superoxide dismutase by singlet oxygen derived from photoactivated dye. Biochimie 2001; 83: 437-444.
63. Wainwright M, Phoenix DA, Gaskell M, Marshall B. Photobactericidal activity of Methylene Blue derivatives against vancomycin-resistant Enterococcus spp. J Antimicrob Chemother 1999; 44: 823-825.
64. Wilson M, Mia N. Effect of environmental factors on the lethal photosensitisation of Candida albicans in vitro. Lasers Med Sci 1994; 9: 105-109.
65. Wainwright M. The emerging chemistry of blood product disinfection. Chem Soc Rev 2002; 31: 128-136.
66. Wainwright M. Pathogen inactivation in blood products. Curr Med Chem 2002; 9: 127-143.
67. Wainwright M. The use of methylene blue derivatives in blood product disinfection. Int J Antimicrob Agents 2000; 16: 381-394.
68. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: Etiology, pharmacology, and clinical management. Ann Emerg Med 1999; 34: 646-656.
69. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: Report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291-294.
70. Schenk P, Madl C, Rezaie-Majd S, et al. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000; 133: 701-706.
71. Daemen-Gubbels CRGH, Groenveld PHP, Groeneveld ABJ, et al. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995; 23: 1363-1370.
72. Gachot B, Bédos JP, Veber B, et al. Short-term effects of methylene blue on haemodynamics and gas exchange in humans with septic shock. Intens Care Med 1995; 21: 1027-1031.
73. Preiser JC, Zhang H, Vincent JL. Administration of methylene blue in septic shock: Is it beneficial? In Vincent JL (ed): Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer, 1994.
74. Martinez Portillo F, Hoang-Boehm J, Weiss J, et al. Methylene blue as a successful treatment alternative for pharmacologically induced priapism. Eur Urol 2001; 39: 20-3.
75. Kluger Y, Weinbroum A, Ben-Avraham, et al. Reduction in formation of peritoneal adhesions by methylene blue in rats: A dose response study. Eur J Surg 2000; 166: 568-571.
76. Blass N, Fung D. Dyed but not dead-methylene blue overdose. Anesthesiology 1976; 45: 458-459.
77. Schultz P, Schwarz GA. Radiculomyelopathy following intrathecal installation of methylene blue. A hazard reaffirmed. Arch Neurol 1970; 22: 240-244.
78. Tiboni GM, Lamonaca D. Transplacental exposure to methylene blue initiates teratogenesis in the mouse: Preliminary evidence for a mechanistic implication of cyclic GMP pathway disruption. Teratology 2001; 64: 213-220.
79. Gauthier TW. Methylene blue-induced hyperbilirubinemia in neonatal glucose-6-phosphate dehydrogenase (G6PD) deficiency. J Matern-Fetal Med 2000; 9: 252-254.
80. Porat R, Gilbert S, Magilner D. Methylene blue-induced phototoxicity: An unrecognized complication. Pediatrics 1996; 97: 717-721.
81. Cragun JD. Teratogen update: methylene blue. Teratology 1999; 60: 42-48.
82. Creagh TA, Gleeson M, Travis D, Grainger R, McDermott TED, Butler MR. Is there a rôle for in vivo methylene blue staining in the prediction of bladder tumour recurrence? Br J Urol 1995; 75: 477-479.
83. Soukos, NS, Wilson M, Burns T, Speight PM. Photodynamic effects of toluidine blue on human oral keratinocytes and fibroblasts and Streptococcus sanguis evaluated in vitro. Lasers Surg Med 1996; 18: 253-259.
84. Millson CE, Thurrell W, Buonaccorsi G, Wilson M, MacRobert AJ, Bown SG. The effect of low power laser light at different doses on gastric mucosa sensitized with methylene blue, haematoporphyrin derivative or toluidine blue. Lasers Med Sci 1997; 12: 145-150.
85. Wainwright M, Phoenix DA, Rice L, Burrow SM, Waring JJ. Increased cytotoxicity and phototoxicity in the methylene blue series via chromophore methylation. J Photochem Photobiol B Biol 1997; 40: 233-239.
86. Watanabe J, Fujita R. Elimination of methylene blue in dogs after oral or intravenous administration. Chem Pharm Bull 1977; 25: 2561-2567.
87. Audi SH, Olson LE, Bongard RD, Roerig DL, Schulte ML. Dawson CA. Toluidine blue O and methylene blue as endothelial redox probes in the intact lung. Am J Physiol 2000; 278: H137-H150.
88. Wagner SJ, Skripchenko A, Robinette D, Foley JW, Cincotta L. Factors affecting virus photoinactivation by a series of phenothiazine dyes. Photochem Photobiol 1998; 67: 343-349.
89. Brecher G. New Methylene Blue as a reticulocyte stain. Am J Clin Pathol 1949; 19: 895-896.
90. Jensen WN, Montjar M, Heinle E, Padilla F, Trakatellis AC. Action du bleu de methylene "nouveau" sur les ribosomes des reticulocytes du rat. Nouv Rev Fr d'Hematol 1967; 7: 841-845.
91. Wainwright M, Phoenix DA, Wareing DRA and Smillie TE. Photobactericidal activity of phenothiaziniums against Yersinia enterocolitica. J Chemother 2001; 13: 503-509.
92. Mellish KJ, Cox RD, Vernon DI, Griffiths J, Brown SB. In vitro photodynamic activity of a sefies of methylene blue analogues. Photochem Photobiol 2002; 75: 392-397.
93. Noodt BB, Rodal GH, Wainwright M, et al. Induction of apoptosis via different pathways by photodynamic therapy with methylene blue derivative localized in mitochondria of V79 cells. Int J Cancer 1998; 75: 941-948.